communicating vaccine safety
  • Prospective Surveillance of Influenza-like Illness (ILI) in Children

    Prospective Surveillance of Influenza-like Illness (ILI) in Children Acute respiratory infections and influenza-like illness are among the most common reasons for children to seek care in emergency rooms. Nevertheless the information provided about the cause of the illness and whether it could have been prevented by vaccines is usually minimal. This often causes confusion among parents and families, especially when the influenza-like illness appears shortly after a seasonal influenza immunization. The ViVI prospective surveillance program has been designed in collaboration with the Charité Medical University and the Robert Koch Institute in Berlin in order to improve vaccine safety communication. The project also assesses how the patient’s immunization history is obtained and documented in the acute care setting. Families should be able to leave the emergency room with concrete immediate feedback about the patient’s type of infection.
  • Prospective Surveillance of Meningitis and Encephalitis in Children

    Prospective Surveillance of Meningitis and Encephalitis in Children An important part of vaccine safety communication is the accurate assessment of potential adverse events following immunization (AEFI). Past research has shown that retrospective chart reviews do not contain the complete clinical information that would allow for the implementation of international case definitions. These international standards however are required for the case ascertainment of AEFI. The ViVI prospective surveillance program for meningitis aims to establish the immediate case ascertainment of rare neurologic AEFI in the acute care setting. The idea was conceptualized by the VIVI think tank to be executed in collaboration with the Charité Medical University and the Robert Koch Institute in Berlin.

    Past research
  • Vaccine Safety Survey for Pediatricians

    Assesing Vaccine Safety Perceptions among Members of Pediatric Professional Societies The objectives of this survey project are as follows:
    1. To assess the degree of involvement in vaccine safety counseling among paediatricians.

    2. To assess awareness of available vaccine safety standards among members of paediatric professional organizations.

    3. To assess perceptions of the applicability of standardized case definitions in the context of Adverse Events After Immunization - AEFI (*) reporting.
    Recent trials have confirmed the safety of recommended vaccines, but rumours surrounding the safety of human vaccines spread quickly via the international and local media and have caused confusion and anxiety among patients, parents and paediatricians alike. In view of these concerns, it is the goal of this project in collaboration with paediatric professional associations, to assess perceptions of vaccine safety among paediatricians around the world and to generate feedback for the scientific community in general and the paediatricians, in particular. It is hoped that the proposed study will be able to generate concepts for evidence based action towards accurate AEFI reporting while strengthening trust in vaccines.

    * An Adverse Event Following Immunization is defined as an untoward medical occurence in a person who was administrated a vaccine; the adverse event does not necessarily have a causal relationship with the vaccination.

    The results of this survey will be published soon.
  • Special Issue „Communicating Vaccine Safety“

    Special Issue „Communicating Vaccine Safety“ The ViVI think tank has invited international experts in vaccine safety to prepare a special journal issue on ‘Communicating Vaccine Safety.’

    The special issue is to be published shortly.
  • Vaccine Safety Training Initiative

    Vaccine Safety Training Initiative In collaboration with student coordinators, ViVI is currently working on the design of innovative teaching tools and programs to improve vaccine safety, innovation, and training during medical school and beyond.